Fluorometholone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Fluorometholone
- Fluorometholone: From Ocular Inflammatory Conditions (Uveitis, Conjunctivitis) to Postinfectious Vasculitis
Fluorometholone: From Ocular Inflammatory Conditions (Uveitis, Conjunctivitis) to Postinfectious Vasculitis
One-Sentence Summary
Fluorometholone is a topical corticosteroid, originally used to treat ocular inflammatory conditions such as uveitis, iritis and iridocyclitis, and conjunctivitis. The TxGNN model predicts it may be effective for postinfectious vasculitis (top-ranked prediction), but there are 0 clinical trials and 0 publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Uveitis and other ocular inflammatory conditions (per the knowledge graph; the Singapore licence has no indication text) |
| Predicted New Indication | Postinfectious vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, fluorometholone is a synthetic corticosteroid that acts on the glucocorticoid receptor (NR3C1). Its anti-inflammatory activity is established in ocular inflammation, so a mechanistic link to other immune-mediated inflammatory conditions is conceivable.
Postinfectious vasculitis is immune-mediated, so a corticosteroid effect is plausible in principle. However, fluorometholone is an ophthalmic suspension with minimal systemic exposure, so it is unlikely to reach therapeutic levels in vascular tissue. The high TxGNN score is a model prediction with no supporting trials or literature.
Other predictions in the top 10 (for context):
| Rank | Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 6 | Punctate epithelial keratoconjunctivitis | 99.89% | L4 | Most biologically plausible; adjacent to approved ocular uses. Two indirect papers only |
| 9 | Lens-induced iridocyclitis | 99.82% | L4 | Closely related to the labelled iritis/iridocyclitis; no specific studies |
| 10 | Glaucomatocyclitic crisis | 99.82% | L4 | Recurrent anterior uveitis with raised eye pressure; indirect, class-level reasoning |
| 3 | Otitis externa | 99.90% | L5 | Class-level extrapolation; ophthalmic product not designed for ear use |
| 2, 4, 5, 7, 8 | Post-bacterial disorder, infective urethral stricture, post-infectious syndrome, infection-related HUS, Chagas cardiomyopathy | 99.87–99.91% | L5 | Implausible or poorly defined; no delivery route or evidence |
If the goal is a practical repurposing lead, the ocular candidates (ranks 6, 9 and 10) are more actionable than the top-ranked prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature is available for postinfectious vasculitis. The only literature in the data relates to the rank 6 prediction (punctate epithelial keratoconjunctivitis), and it is indirect evidence:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35128186 | 2021 | Cohort | Journal of Current Ophthalmology | Anterior segment OCT used to monitor phases of epidemic keratoconjunctivitis and the effect of topical steroid on its course |
| 34011737 | 2021 | Review | Indian Journal of Ophthalmology | Sequelae and management of microsporidial keratoconjunctivitis |
Neither paper tests fluorometholone efficacy directly.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04347P | FML Liquifilm Ophthalmic Suspension 0.1% (Allergan Pharmaceuticals Ireland) | Solution | Not stated in the registration data |
Safety Considerations
Contraindications (from knowledge graph, not label text): herpes simplex virus keratitis, viral eye infection, fungal infection of eye, ocular tuberculosis, eye infectious disease, conjunctivitis (infective), open-angle glaucoma, ocular hypertension, diabetes mellitus, diabetic ketoacidosis, porphyria (including inherited porphyria and porphyrin metabolism disease), G6PD deficiency, glycogen storage disease, cystinuria, galactosemia, corneal pigmentation.
These come from knowledge graph edges and should be verified against the package insert.
Drug Interactions: 11 potential interactions were identified, all with an unclassified severity level: doxycycline, salbutamol, cyclosporine, acetaminophen, digoxin, brimonidine, cephalexin, alendronic acid, acyclovir, diazepam and fenofibrate.
Additional cautions for new indications:
- Steroid use in infectious keratoconjunctivitis risks prolonging infection, raising intraocular pressure and delaying healing.
- Use in otitis externa would be a concern if the tympanic membrane is perforated.
- Steroids may risk parasite reactivation in Chagas disease.
Please refer to the package insert for full safety information. The HSA package insert warnings and contraindications have not yet been obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, postinfectious vasculitis, has no clinical trials or literature (evidence level L5). A topical ocular steroid with minimal systemic exposure is also unlikely to be effective for a systemic vascular condition. Any further work should focus on the ocular candidates (punctate epithelial keratoconjunctivitis, lens-induced iridocyclitis, glaucomatocyclitic crisis), which are better supported mechanistically and could be treated as research questions.
To proceed, the following is needed:
- HSA package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data
- Direct clinical or observational evidence for fluorometholone in the candidate indication
- Route and exposure compatibility assessment (ophthalmic formulation versus the target tissue)
- Review of the ocular candidates, with intraocular pressure and infection risk monitoring plans
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.